WaveBot: The Automated Trading Tool for This Bull Market

The 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But here’s the thing: most people won’t be able to keep up with the pace of the market. That’s why I want to tell you about WaveBot – an automated trading tool created by my good friends Joel and Adam.

Etienne Montagut net worth and biography

Etienne Montagut Biography and Net Worth

Insider of Lantheus

Etienne Montagut joined Lantheus as Senior Vice President, Corporate Development in September 2018. Mr. Montagut brings to the Company more than 20 years of commercial, portfolio management and business development & licensing experience. Prior to joining Lantheus, Mr. Montagut spent the last six years with GE Healthcare, the $19 billion healthcare business of GE (NYSE: GE) and a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies. He held various senior leadership roles at GE Healthcare, including General Manager, Global SPECT Portfolio & Director of Cardiology, Executive, Global Product Leader SPECT Neurology & Cardiology, and most recently as Executive, General Manager Molecular Imaging Greater China. Prior to GE Healthcare, while at Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group focused on innovation and specialty care, Mr. Montagut held both commercial and corporate positions, including Corporate Commercial Development, Business Development & Licensing and Portfolio Management. Mr. Montagut holds a Master of Business Administration from Imperial College, London, and a Master of Business Intelligence from EGE in Paris.

What is Etienne Montagut's net worth?: The estimated net worth of Etienne Montagut is at least $6.02 million as of April 17th, 2023. Mr. Montagut owns 67,254 shares of Lantheus stock worth more than $6,024,613 as of December 3rd. This net worth approximation does not reflect any other investments that Mr. Montagut may own. Learn More about Etienne Montagut's net worth.
How do I contact Etienne Montagut?: The corporate mailing address for Mr. Montagut and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected]. Learn More on Etienne Montagut's contact information.
Has Etienne Montagut been buying or selling shares of Lantheus?: Etienne Montagut has not been actively trading shares of Lantheus during the last ninety days. Most recently, Etienne Montagut sold 2,118 shares of the business's stock in a transaction on Monday, April 17th. The shares were sold at an average price of $88.67, for a transaction totalling $187,803.06. Following the completion of the sale, the insider now directly owns 67,254 shares of the company's stock, valued at $5,963,412.18. Learn More on Etienne Montagut's trading history.
Who are Lantheus' active insiders?: Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (CEO & Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Gary Pruden (Director), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.
Are insiders buying or selling shares of Lantheus?: During the last year, Lantheus insiders bought shares 1 times. They purchased a total of 60,431,039 shares worth more than $57,409,487.05. During the last year, insiders at the medical equipment provider sold shares 13 times. They sold a total of 167,666 shares worth more than $12,647,453.05. The most recent insider tranaction occured on August, 12th when Director Gerard Ber sold 15,500 shares worth more than $1,495,440.00. Insiders at Lantheus own 2.1% of the company. Learn More about insider trades at Lantheus.
Information on this page was last updated on 8/12/2024.

Etienne Montagut Insider Trading History at Lantheus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/17/2023	Sell	2,118	$88.67	$187,803.06	67,254
4/3/2023	Sell	3,684	$82.09	$302,419.56	69,372
3/27/2023	Sell	14,528	$81.13	$1,178,656.64	73,056
3/6/2023	Sell	14,179	$72.56	$1,028,828.24	90,825
10/18/2022	Sell	2,536	$73.41	$186,167.76	81,999
4/4/2022	Sell	12,655	$57.38	$726,143.90	83,975
10/18/2021	Sell	2,364	$22.90	$54,135.60
6/4/2021	Sell	7,435	$24.60	$182,901.00	87,719

Etienne Montagut Buying and Selling Activity at Lantheus

Lantheus Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Today's Range

Now: $87.35

$86.87

$89.94

50 Day Range

MA: $100.90

$76.22

$116.69

2 Week Range

Now: $87.35

$50.20

$126.89

Volume

174,344 shs

Average Volume

1,017,873 shs

Market Capitalization

$6.07 billion

P/E Ratio

14.53

Dividend Yield

N/A

Beta

0.45